BiotechTube
Perosphere Technologies

Perosphere Technologies

Danbury, United States· Est.
perospheretech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $55M

Overview

Perosphere Technologies is a U.S.-based, private diagnostics company founded in 2008, specializing in point-of-care coagulation testing. Its core technology is the Perosphere ClotChek system, a CE-marked device that performs a whole blood clotting time (WBCT) assay with lab-like precision in 3-8 minutes, without reagents. The company is led by a seasoned team with deep expertise in diagnostics, medical devices, and business operations, and is positioned to address a significant need for rapid coagulation monitoring in various clinical settings. Currently, the device is not FDA-cleared, limiting its commercial reach to markets recognizing the CE mark.

Coagulation Disorders

Technology Platform

Point-of-care, handheld coagulometer using a reagent-free Whole Blood Clotting Time (WBCT) assay to provide a rapid, global view of coagulation status.

Funding History

2
Total raised:$55M
Series B$30M
Series A$25M

Opportunities

The growing need for rapid, point-of-care coagulation testing in acute care settings (OR, ER, ICU) and for managing patients on anticoagulants presents a large market.
The ClotChek's unique reagent-free, global assay could differentiate it from existing tests that measure specific pathways, filling a gap for holistic, rapid assessment.

Risk Factors

The primary risk is the lack of FDA clearance, blocking access to the large U.S.
market.
Additional risks include challenges in commercial adoption against established competitors, the need to demonstrate clear clinical utility to change physician behavior, and dependence on external funding as a private company.

Competitive Landscape

The point-of-care coagulation testing market is competitive, dominated by large diagnostics companies like Roche (CoaguChek), Abbott (i-STAT), and Werfen. Perosphere's ClotChek competes by offering a reagent-free, global clotting time, positioning it as a complementary or alternative tool for rapid, holistic assessment rather than a direct replacement for drug-specific tests like INR.

More companies in United States →